Barosi G, Liberato L N, Costa A, Buratti A, Di Dio F, Salvatore S, Ascari E
Dipartimento di Medicina Interna e Terapia Medica (Sez. Clinica Medica 2), IRCCS Policlinico S. Matteo, Pavia, Italy.
Eur J Haematol Suppl. 1990;52:12-4. doi: 10.1111/j.1600-0609.1990.tb00898.x.
In 12 patients having myelofibrosis with myeloid metaplasia (MMM), recombinant- alpha interferon (r-alpha INF) was given for 16 weeks at an initial dose of 3 x 10(6) U/day as a cytoreductive agent. At the end of the 16th wk, Hb showed minor changes; WBC were reduced from 43 x 10(9)/l, range 6.4-69.4, to 16 x 10(9)/l, range 5-39 (p = 0.05); platelets decreased from 845 x 10(9)/l, range 215-1748, to 370 x 10(9)/l, range 96-730 (p = 0.005). 2 cases responded at the starting dose, while the effective dose was 5 x 10(6) U/d in the others. Minor changes in spleen size were noted, while no significant changes in bone marrow fibrosis occurred. After induction therapy, 3 patients were allocated to maintenance therapy (from 10 up to 34 months). To maintain platelet count lower than 500 x 10(9)/l, the required r-alpha-INF dose was constantly 10 MU/wk, while the same result was not achieved in 1 case with hydroxyurea, 1 g/die. The association with hydroxyurea, 500 mg/die, allowed reduction of the r-alpha INF dose to 6 MU/die in 1 other case.
在12例骨髓纤维化伴髓外化生（MMM）患者中，给予重组α干扰素（r-α INF）作为细胞减灭剂，初始剂量为3×10⁶ U/天，持续16周。在第16周结束时，血红蛋白显示轻微变化；白细胞计数从43×10⁹/L（范围6.4 - 69.4）降至16×10⁹/L（范围5 - 39，p = 0.05）；血小板计数从845×10⁹/L（范围215 - 1748）降至370×10⁹/L（范围96 - 730，p = 0.005）。2例患者在起始剂量时出现反应，而其他患者的有效剂量为5×10⁶ U/天。脾脏大小有轻微变化，而骨髓纤维化无显著改变。诱导治疗后，3例患者接受维持治疗（持续10至34个月）。为使血小板计数维持在低于500×10⁹/L，所需的r-α INF剂量持续为10 MU/周，而1例使用羟基脲（1 g/天）的患者未达到相同效果。在另1例患者中，联合使用500 mg/天的羟基脲可使r-α INF剂量降至6 MU/天。
